HER2 as a therapeutic target in head and neck squamous cell carcinoma
NI Pollock, JR Grandis - Clinical Cancer Research, 2015 - AACR
The majority of patients with head and neck squamous cell carcinoma (HNSCC) present
with advanced-stage disease. The current standard of care is surgery followed by adjuvant …
with advanced-stage disease. The current standard of care is surgery followed by adjuvant …
Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors
AG Sacco, FP Worden - OncoTargets and therapy, 2016 - Taylor & Francis
The majority of patients with head and neck squamous cell carcinoma (HNSCC) present
with locally advanced disease, which requires site-specific combinations of surgery …
with locally advanced disease, which requires site-specific combinations of surgery …
[HTML][HTML] Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA)
GF Shen, TT Liu, Q Wang, M Jiang, JH Shi - Journal of Photochemistry and …, 2015 - Elsevier
The binding interactions of three kinds of tyrosine kinase inhibitors (TKIs), such as gefitinib,
lapatinib and sunitinib, with bovine serum albumin (BSA) were studied using ultraviolet …
lapatinib and sunitinib, with bovine serum albumin (BSA) were studied using ultraviolet …
FOXO3a represses VEGF expression through FOXM1-dependent and-independent mechanisms in breast cancer
CT Karadedou, AR Gomes, J Chen, M Petkovic, KK Ho… - Oncogene, 2012 - nature.com
Vascular endothelial growth factor (VEGF) has a central role in breast cancer development
and progression, but the mechanisms that control its expression are poorly understood …
and progression, but the mechanisms that control its expression are poorly understood …
[HTML][HTML] Macrophages M2 polarization is involved in lapatinib-mediated chemopreventive effects in the lung cancer
M2 polarized tumor-associated macrophages (TAMs) have a multifunctional role in cancer
initiation, progression, metastasis, and contribute to chemotherapeutic resistance. Therefore …
initiation, progression, metastasis, and contribute to chemotherapeutic resistance. Therefore …
Targeted therapy in head and neck cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies
J Moreira, A Tobias, MP O'Brien, M Agulnik - Drugs, 2017 - Springer
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
The role of STAT3 signaling in mediating tumor resistance to cancer therapy
FH Tan, TL Putoczki, SS Stylli… - Current drug targets, 2014 - ingentaconnect.com
Signal transducer and activator of transcription 3 (STAT3) is activated in many cancer types
and can regulate pathways involving tumorigenesis, cell proliferation, cell survival and …
and can regulate pathways involving tumorigenesis, cell proliferation, cell survival and …
Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma
A Markovic, CH Chung - Expert review of anticancer therapy, 2012 - Taylor & Francis
New agents and treatment strategies that can be safely and effectively integrated into current
treatment paradigms for head and neck squamous cell carcinoma (HNSCC) are urgently …
treatment paradigms for head and neck squamous cell carcinoma (HNSCC) are urgently …
[HTML][HTML] New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
M Agulnik - Medical Oncology, 2012 - Springer
Despite recent advances in radiotherapy and chemotherapy, survival rates for squamous
cell carcinoma of the head and neck (SCCHN) have remained poor. The focus of SCCHN …
cell carcinoma of the head and neck (SCCHN) have remained poor. The focus of SCCHN …
[HTML][HTML] Rapid self-assembly of polymer nanoparticles for synergistic codelivery of paclitaxel and lapatinib via flash nanoprecipitation
SL Levit, H Yang, C Tang - Nanomaterials, 2020 - mdpi.com
Taxol, a formulation of paclitaxel (PTX), is one of the most widely used anticancer drugs,
particularly for treating recurring ovarian carcinomas following surgery. Clinically, PTX is …
particularly for treating recurring ovarian carcinomas following surgery. Clinically, PTX is …